MET and hepatocellular carcinoma: Tumour shrinkage was generally greater in patients with HCC with MET overexpression; both patients who achieved PR had HCC with MET overexpression (n = 1, IHC 2+, 1,000 mg cohort, and n = 1, IHC 3+, 500 mg cohort) (Fig. 1).